Looking for space?
Login

Citryll Demonstrates a Broader Therapeutic Potential for CIT-013 in the Treatment of Inflammatory Disorders

Oss, Netherlands – 20 February 2025 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), today announces the publication of new research in Frontiers in Immunology. The study demonstrates that CIT-013, originally developed to target NETs, also effectively inhibits the formation of eosinophil extracellular traps (EETs) with the same potency and verifies the presence of CIT-013’s epitope on EETs. These findings further validate Citryll’s approach and highlight the broader therapeutic potential of CIT-013 beyond inflammatory diseases that are neutrophilic in nature.

CIT-013, Citryll’s first-in-class monoclonal antibody, has previously demonstrated its ability to inhibit NET formation in Phase 1 clinical trials. Extracellular traps (ETs) are web-like structures composed of DNA, histones, and antimicrobial proteins, released by cells to trap and degrade pathogens. Excessive ET formation can contribute to tissue damage and chronic inflammation in various immune-mediated inflammatory disorders. Citryll is currently investigating CIT-013 in rheumatoid arthritis (RA) and hidradenitis suppurativa (HS).

This latest preclinical study highlights CIT-013’s ability to inhibit EET formation. The presence of CIT-013’s epitope on EETs will also enable CIT-013 to bind and enhance the phagocytic clearance of tissue EETs, as previously established for NETs.

Importantly, the study demonstrated that CIT-013’s dual mechanism of action – enhancing the clearance of existing extracellular traps and preventing the formation of new ones – applies equally to eosinophils, another type of white blood cell, reinforcing its potential as a therapy capable of targeting extracellular traps regardless of their cellular origin.

The release and accumulation of EETs in inflamed tissue have been observed in multiple inflammatory diseases. These findings reinforce CIT-013’s potential to treat a broad range of ET-driven inflammatory conditions, including cardiovascular and respiratory diseases, where multiple cell types contribute to inflammation.

These results follow Citryll’s recent €85 million Series B funding round, which supports the advancement of CIT-013 into Phase 2a clinical trials for RA and HS. These trials will further establish CIT-013’s unique dual mode of action, enhancing the clearance of existing NETs while preventing the formation of new ones. CIT-013 is highly selective for its epitope, minimising off-target effects, and does not enter cells, preserving normal intracellular functions.

For more information click here.

Find more news here.

Citryll
Search

Recent Posts

Looking for
space to grow?

More information
Join us at Pivot Park

Learn about
our companies?

Send us a message
Contact us at Pivot Park

or call

+31 (0)412 84 60 10

Linkedin-in Youtube
Address

Pivot Park – Building RK
Kloosterstraat 9
5349 AB Oss
The Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com

Post address

Pivot Park  Exploitatie B.V. 
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands

Disclaimer  |  Privacy Statement  |  Cookie Statement  |  Purchase conditions

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?
Read more (NL)

#100YEARSPHARMAFUTURE

The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.